Neuroblastoma cell

The neuroblastoma cell is a malignant cell originating from the neural crest, primarily affecting the sympathetic nervous system in infants and young children (NIH, 2023). These cells are the hallmark of neuroblastoma, a heterogeneous cancer that ranges from spontaneous regression to highly aggressive metastatic disease (StatPearls, 2023). Key molecular features of these cells include the overexpression of the GD2 ganglioside and frequent genetic aberrations such as MYCN amplification and ALK mutations, which drive uncontrolled proliferation and survival (PubMed, 2021). While "neuroblastoma cells" are often cited as the focus of research, they represent a complex disease state rather than a single therapeutic target. Therapeutic strategies involve targeting specific proteins or pathways within these cells, such as using monoclonal antibodies like dinutuximab to target GD2 or small molecule inhibitors for ALK (NCI, 2024). Additionally, differentiation therapy using retinoids is employed to force these immature cells into a more mature, non-proliferative state (PubMed, 2022).

Other names

NB cellsNeuroblastoma cell linesMalignant neural crest cells

Therapeutic interventions against neuroblastoma cells utilize diverse mechanisms: alkylating agents (e.g., cyclophosphamide) cause DNA damage; topoisomerase inhibitors (e.g., etoposide) prevent DNA ligation; microtubule inhibitors (e.g., vincristine) arrest mitosis; and retinoids (e.g., isotretinoin) induce cell differentiation (PubMed, 2022). Targeted therapies include anti-GD2 antibodies that trigger antibody-dependent cell-mediated cytotoxicity (ADCC) and ALK inhibitors that block oncogenic signaling (NIH, 2023).